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ABSTRACT 
Berardinelli – Seip congenital lipodystrophy (BSCL) is an inherited form of generalized lipodystrophy characterized by loss of 
subcutaneous fat, hypertriglyceridemia, insulin resistance and acanthosis nigricans. Rare cases of BSCL type 2 present during 
infancy or early childhood. It is caused by mutation in Seipin gene. It is a severe phenotype with premature death occurring in 
15% cases. We present such a rare case of BSCL in a five month old infant.  
Key words: Hypertriglyceridemia, Insulin resistance, Lipodystrophy, Phlebomegaly 
erardinelli - Seip congenital lipodystrophy 
(BSCL) is an autosomal recessive disorder 
characterized by generalized complete absence of 
subcutaneous fat and the presence of muscle hypertrophy, 
hyperlipidemia, diabetes mellitus, acanthosis nigricans and 
hepatosplenomegaly with cirrhosis. Approximately 300 
patients have been registered in various ethnic origins [1]. 
BSCL has been classified into 3 groups which are BSCL1, 
BSCL2 and BSCLX. BSCL 1 is due to defective 1-
acylglycerol-3-phosphate-O-Acyltransferase-2 (AGPAT) 
gene on chromosome 9q34 where as in BSCL2 the gene 
involved is Seipin gene located on chromosome 11q13. 
BSCLX doesn’t show evidence of either mutation. In all 
forms of congenital generalized lipodystrophy, there is 
complete absence of subcutaneous fat and abnormal fat 
storage in muscle and liver with various metabolic 
problems. The estimated prevalence of this rare disease is 
0.25 in 100,000 populations and only 12 cases of BSCL 
have been reported in India [2]. 
CASE REPORT 
A five month old male baby (figure 1) born out of 2
nd
 
degree consanguinous marriage presented with enlarged 
stubby hands and feet, abdominal distension and absence 
of fat pad affecting face, trunk and limbs since birth. There 
was no history of feeding intolerance, vomiting, loose 
motions convulsions His antenatal, natal and postnatal 
history was non-contributory with no significant family 
history. He was exclusive breast fed till date and was 
accepting feeds well. On examination, baby was 
conscious, active and stable vital signs. On general 
examination, he had coarse facies, enlarged prominent 
veins all over his body (figure 2), and yellowish nodules 
over knee, and elbow. On systemic examination, he had 
hepatosplenomegaly while rest of the systemic 
examination was non-significant.  
His routine laboratory investigations including 
complete blood count, C reactive protein, serum 
electrolytes, and renal and liver function tests were within 
normal limits. His fasting blood sugar was high (225 
mg/dl). His total serum protein was elevated (10.08 
gm/dl), and serum albumin was 4.08 gm/dl. Yellowish 
nodules over the body were suggestive of xanthoma; 
therefore, his serum lipid profile was sent. His serum was 
milky white with elevated triglyceride (TG) levels (figure 
3). Serum TG was 1845 mg/dl, serum cholesterol was 148 
mg/dl, LDL cholesterol was 88 mg/dl, and total cholesterol 
to HDL cholesterol ratio - 7.4. Investigations done to 
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establish the cause of hyperglycemia showed high serum 
insulin level (14.12 μIU/ml), and HbA1C (15.7%). 
Ultrasonography of abdomen revealed fatty liver, and 
chest X-ray was showing cardiomegaly with CT ratio 
62%; however, echocardiography revealed no structural 
abnormality.  
 
Figure 1 - Distended abdomen with loss of buccal fat 
pad and course facies 
 
Figure 2 - prominent superficial veins over lower limbs 
 
Figure 3 - milky white serum compared with normal 
serum 
Biopsy of nodules over knee was done and sent for 
histopathological examination which was suggestive of 
xanthoma. X-ray of limbs did not show presence of bone 
cysts. Genetic diagnosis could not be done in this patient 
due to non-availability of this facility in our set up. Since, 
he had three of the major criteria; he was diagnosed with 
BSCL and as the clinical presentation was during infancy 
with more severe form it was presumed to be type 2 
BSCL. 
DISCUSSION 
Clinical presentation of our patient was consistent with 
Berardinelli – Seip Congenital lipodystrophy - 2 variety; 
although, diagnosis could not be confirmed by genetic 
analysis. BSCL type 2 is a rare autosomal recessive 
disorder caused by mutation in the Seipin gene which 
equally affects males and females. BSCL 1 is a less severe 
form and can present between 2
nd 
and 3
rd
 decade where as 
BSCL2 presents in neonatal period, infancy and early 
childhood. Major criteria for diagnosis of BSCL are 
lipoatrophy, acromegaloid features, hepatomegaly, 
elevated serum triglycerides, and insulin resistance. Minor 
criteria are hypertrophic cardiomyopathy, psychomotor 
retardation, hirsuitism, precocious puberty and bone cysts. 
Diagnosis requires presence of three major criteria or two 
major and two minor criteria to be fulfilled [3].  
The BSCL-2 locus (Seipin gene) is identified within 
2.5 Mb interval flanked by markers D11S4076 and 
D11S4080 on chromosome 11q13 [1]. Seipin gene plays a 
role in lipid droplet formation and adipocyte 
differentiation [4]. Marked lipodystrophy occurs at birth or 
early infancy [5]. Lipodystrophies produce distinctive 
facies and a well defined musculature with prominent 
superficial veins (phlebomegaly) is one of the earliest 
manifestations. Anabolic features are observed at birth 
with enlarged visceral organs. Even toddlers have 
hyperplasia of pharyngeal tonsils and adenoids. Later 
during childhood, acanthosis nigricans develop on 
extensive areas of skin most prominently on elbows, 
knees, waist, neck and axilla and can diminish or disappear 
during puberty [4]. Other skin manifestations are eruptive 
xanthoma and hirsuitism.  
Only few patients develop diabetes during infancy but 
most often diabetes develops during teenage year. 
Hyperlipidemia usually precedes diabetes in these patients 
and diabetes is usually insulin resistant and ketosis is 
absent despite poor control. Other features are enlarged 
hands, feet and prominent mandible (acromegaloid 
features). Lytic lesions may present in long bones of upper 
and lower extremities [6]. Congenital generalized 
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lipodystrophy with lytic lesions in bone is also termed as 
Brunzell Syndrome. Females present with enlarged 
clitoris, increased body hair, absence of or irregular 
menstrual cycles and polycystic ovaries. Mental 
subnormality and low IQ commonly is seen more 
commonly in BSCL type 2 variant than in BSCL1. 
Cardiomegaly is frequently observed with muscular 
hypertrophy and arterial hypertension [7]. 
Treatment of acanthosis nigricans is done by Etretinate. 
Dietary fish oil is also useful [8]. Use of medium chain 
triglyceride can result in improving hypertriglyceridemia, 
hepatomegaly and insulin resistance. But it has no effect 
on lipoatrophy. Fibre content of diet should be higher and 
easily digestible carbohydrates should be restricted [9]. 
Patients should be provided with rigid meal schedule as 
they have limited ability to store energy. Leptin 
replacement can reverse metabolic complications in 
majority of the children with BSCL and with insulin 
resistance or dyslipidemia before development of overt 
diabetes [10]. Patients can survive upto young adulthood 
or early middle age. Common causes of death are renal 
failure, upper GI bleeding due to esophageal varices 
resulting from hepatic failure [11]. 
CONCLUSION 
BSCL type 2 is an adipose tissue disorder characterized by 
abnormal fat distribution with metabolic problems. 
Patients with this condition should be regularly followed 
up and monitored for metabolic derangements. During 
follow up visits, tanner’s staging, neurological, 
endocrinological, cardiovascular, ophthalmologic and 
orthopedic evaluation should be done. Patients should 
consume low fat diet and regular physical exercise should 
be encouraged to postpone metabolic problems.  
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